Novel small molecule modulator of the gp130 receptor shows dose-dependent therapeutic efficacy in a canine model of osteoarthritis

Purpose: The pathogenesis of OA often begins from an injury to articular cartilage, which establishes chronic, low-grade inflammation principally mediated by IL-6 family cytokines that signal through the obligate receptor gp130; this promotes matrix degradation leading to the destruction of cartilage. Currently, there are no agents that efficiently slow or inhibit this process. Here, we unveil an advanced late pre-clinical candidate CX-011 that has significant, dose-dependent effects on joint structure, function and pain via modulation of gp130.

Source: Osteoarthritis and Cartilage - April 29, 2023 Category: Rheumatology Authors: B. Van Handel, C. Flynn, N. Liu, J. Lu, N. Lane, M. Hurtig, D. Evseenko Source Type: research